How to Cite
Abstract
The study aimed to assess combined treatment with mTOR inhibitor rapamycin and cytotoxic drugs (doxorubicin and paclitaxel) on two models of transplantable tumors - mammary adenocarcinoma in male HER-2/neu transgenic FVB/N mice and solid Ehrlich carcinoma in male 129/Sv mice. Rapamycin (total dose of 3.6 mg kg), doxorubicin (total dose of 15 mg/ kg), paclitaxel (total dose of 6 mg/kg) or their combination were intraperitoneally injected to mice with developed tumor node. Rapamycin showed its own antitumor activity by tumor growth inhibition up to 42% in mammary adenocarcinoma model and up to 57% in Ehrlich carcinoma model. A tendency to an increase in the antitumor activity of chemotherapeutic drugs with the addition of rapamycin was revealed. The cyto-protective effect of the mTOR inhibitor was observed during therapy with doxorubicin and paclitaxel, expressed in a significant decrease in the level of apoptosis in normal epithelium of jejunum crypts. Thus, revealed protective effect of mTOR inhibitor on jejunum epithelium could be applied for reduction of chemotherapeutic drugs enterotoxic effect without any efficiency reduction. Thus, in perspective that could expand the possibilities of standard chemotherapeutic treatment and improve the quality of life of cancer patients.References
Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004; 18(16):1926-1945. DOI: 10.1101/gad.1212704
Blagosklonny MV. Aging: Ros or TOR. Cell Cycle. 2008; 7(21): 3344-3354. DOI: 10.4161/cc.7.21.6965
stanfel MN, shamieh Ls, Kaeberlein M, Kennedy BK. The ToR pathway comes of age. Biochim Biophys Acta. 2009; 1790(10):1067-1074. DOI: 10.1016/j.bbagen.2009.06.007
Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007; 12(1):9-22. DOI: 10.1016/j.ccr.2007.05.008
Apontes P Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget. 2011; 2(3):222-233. DOI: 10.18632/oncotarget.248
Conciatori F, Ciuffreda L, Bazzichetto C, et al. mTOR Cross-Talk in Cancer and Potential for Combination Therapy. Cancers (Basel). 2018; 10(1):23. DOI: 10.3390/cancers10010023
Blagosklonny MV. Rapalogs in cancer prevention: anti-aging or anticancer?. Cancer Biol Ther. 2012; 13(14):1349-1354. DOI: 10.4161/cbt.22859
Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB, Meric-Bernstam F. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res. 2004; 10(20):7031-7042. DOI: 10.1158/1078-0432
Shafer A, Zhou C, Gehrig PA, Boggess JF, Bae-Jump VL. Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis. Int J Cancer. 2010; 126(5):1144-1154. DOI: 10.1002/ijc.24837
Юрова М.Н., Сафина Д.Р., Мизгирев И.В. Селективное ингибирование krasсигнального каскада при комбинированном воздействии низких доз рапами-цина и паклитаксела in vivo // Успехи молекулярной онкологии. - 2018. -Т.5. - № 2. - С. 42-49.
van Leeuwen IM. Cyclotherapy: opening a therapeutic window in cancer treatment. Oncotarget. 2012;3(6):596-600. DOI: 10.18632/oncotarget.524
Kranz D, Dobbelstein M. A killer promoting survival: p53 as a selective means to avoid side effects of chemotherapy. Cell Cycle. 2012; 11(11):2053-4. DOI: 10.4161/cc.20698
Panchenko AV, Popovich IG, Trashkov AP, Egormin PA, Yurova MN, Tyndyk ML, Gubareva EA, Artyukin IN, Vasiliev AG, Khaitsev NV, Zabezhinski MA, Anisimov VN. Biomarkers of aging, life span and spontaneous carcinogenesis in the wild type and HER-2 transgenic FVB/N female mice. Biogerontology. 2016; 17(2):317-24. DOI: 10.1007/s10522-015-9611-y
Wang H, Li D, Li X, et al. Mammalian target of rapamycin inhibitor RAD001 sensitizes endometrial cancer cells to paclitaxel-induced apoptosis via the induction of autophagy. Oncology Letters. 2016; 12(6):5029-5035. DOI: 10.3892/ol.2016.5338
Zou H, Li L, Garcia Carcedo I, et al. Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis. International Journal of Nanomedicine. 2016; 11:1947-1958. DOI: 10.2147/IJN.S100744
Piguet AC, semela D, Keogh A, Wilkens L, stroka D, Stoupis C, et al. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol. 2008; 49:78-87. DOI: 10.1016/j.jhep.2008.03.024
Iorio AL, Da Ros M, Pisano C, de Martino M, Genitori L, sardi I. Combined Treatment with Doxorubicin and Rapamycin Is Effective against In Vitro and In Vivo Models of Human Glioblastoma. J Clin Med. 2019; 8(3):331. DOI: 10.3390/jcm8030331
Campone M, Levy V, Bourbouloux E, et al. Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. British Journal of Cancer. 2009; 100(2):315-321. DOI: 10.1038/sj.bjc.6604851
Hurvitz SA, Dalenc F, Campone M, et al. A Phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overex-pressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Res Treat. 2013; 141:437446. DOI: 10.1007/s10549-013-2689-5
Bent EH, Gilbert LA, Hemann MT. A senescence secretory switch mediated by PI3K/AKT/mTOR activation controls chemoprotective endothelial secretory responses. Genes Dev. 2016; 30(16):1811-1821.
Song Y Xue H, Liu TT, Liu JM, Chen D. Rapamycin plays a neuroprotective effect after spinal cord injury via antiinflammatory effects. J Biochem Mol Toxicol. 2015; 29(1):29-34. DOI: 10.1002/jbt.21603
Wang Z, Song L, Zhang H, Yuan N, Zhang S. [Rapamycin decreases irradiation-induced hematopoietic system damage]. Zhonghua Xue Ye Xue Za Zhi. 2015; 36(4):321-5. DOI: 10.3760/cma.j.issn.0253-2727.2015.04.014
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2019